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New advances in medicine often raise
challenges, and none more so than those
involving the manipulation of human
oocytes and embryos. Issues around clin-
ical need and ethical considerations must
be taken into account, as well as the safety
of the proposed technique. The discussion
around the proposed mitochondrial re-
placement techniques to prevent the
transmission of mitochondrial DNA dis-
ease has perhaps raised more challenges
than most [1].
Mitochondrial DNA diseases are both
common and, in their severest forms,
devastating [2]. There are limited treat-
ments available for these patients, and
those that are successful are focused on
treating complications such as epilepsy
and cardiac disease [3]. Mitochondrial
DNA diseases are transmitted maternally,
and for families carrying these mutations,
a major, and justifiable, desire is to have
unaffected children. For some women,
preimplantation or prenatal diagnosis
may be helpful [4,5], but for other women,
these techniques will not result in disease-
free offspring and the only options avail-
able are either oocyte donation or mito-
chondrial replacement at the oocyte or
zygote stage. The need for this technique
for these families is well established, as are
the experimental methods that are re-
quired for mitochondrial replacement [6–
8]. The major scientific concerns for those
of us working in the field revolve around
safety and efficacy.
In the United Kingdom, the Human
Fertilisation and Embryology Authority
(HFEA) recently considered the safety
issues after extensive expert and public
consultation [9]. This independent group of
scientists reviewed all the evidence and
concluded that mitochondrial replacement
techniques have the potential to be used for
patients with mitochondrial DNA disease,
although further experiments are required
before introduction into clinical practice, to
provide further reassurance with respect to
efficiency and safety. Recently [10], it has
been suggested that the possibility of a
harmful interaction between the mitochon-
drial and nuclear genomes has not been
given due weight. Should we therefore stop
further clinical developments in this area
with immediate effect?
The authors raise an interesting evolu-
tionary argument that the human mito-
chondrial genome co-evolves with the
nuclear genome in females, raising the
possibility of a conflict with the paternal
nuclear genome. They suggest Leber’s
hereditary optic neuropathy (LHON) and
male infertility could be potential exam-
ples of this in humans [10]. Firstly, LHON
is not a male-limited disease as they
suggest [11]. The disorder affects ,10%
of women carrying specific mtDNA mu-
tations, and although there is increased
penetrance in males, strenuous efforts
have failed to identify a nuclear modifier
gene to date, and the increased penetrance
in men could simply reflect the absence of
oestrogens [12]. As regards male infertility,
there is no convincing evidence in man
that inherited variants of mtDNA are at all
relevant in the general population [13,14].
Indeed it is interesting that even in male
patients with pathogenic mitochondrial
DNA mutations, such as LHON, reduced
fertility has not been reported to be a
major clinical feature.
The studies in macaques are also highly
relevant to the risks proposed in humans
associated with mitochondrial replace-
ment. There are now multiple reports of
the health status of the offspring born after
mitochondrial replacement, and all have
shown no difference between these off-
spring and controls [6,7,15]. As highlight-
ed in the reports, the macaques used for
these experiments were not, as suggested
by the authors of the recent commentary
[10], highly genetically related, but some
were from divergent subspecies with
extensive differences in the rhesus ma-
caque genome [6]. Thus, the experiments
using the animal model closest to man
have not shown any adverse effects from
mitochondrial transfer.
Some studies in laboratory mice have
proposed a nuclear DNA–mitochondrial
DNA interaction, but there are others
that have reported no defect despite the
use of very divergent genomes [16–18]. It
is important to recognise that these
studies, and those in invertebrates, have
been performed on highly inbred species
(often inbred over thousands of genera-
tions) and the relevance to human
populations must be questioned. Most
human populations are outbred with
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considerable mixing of the genome over
recent generations. In these populations
the mixing of alleles will inevitably dilute
the effect of potentially harmful nuclear
DNA-mitochondrial DNA interactions.
There has never been any direct evidence
of a ‘‘mismatch’’ between the two in
humans—either on an evolutionary scale
or in the context of disease. This is even
the case for couples from divergent
haplogroups, where potential nuclear-
mitochondrial mismatches are at their
most extreme. Thus, from the mitochon-
drial DNA perspective, any mitochondrial
transfer experiment is just recapitulating
what is happening every day all around
the world—and without any known
adverse effects.
Whilst we accept that any new tech-
nique is associated with risk, we think
the lack of any reliable evidence of
mitochondrial-nuclear interaction as a
cause of disease in human outbred popu-
lations provides the necessary reassurance
to proceed. The recent studies in ma-
caques after mitochondrial replacement
are also supportive that the possible
harmful interactions are unlikely to occur
in man [6,7]. Human preimplantation
embryos and embryonic stem cells gener-
ated with ‘‘unmatched’’ mtDNA replace-
ment demonstrated normal development
and differentiation potential [7,8]. As
suggested by the HFEA [9], it is possible
to match mitochondrial haplotype be-
tween the mother and the mitochondrial
donor to avoid any concern, even though
the evidence says it should not be needed.
We do not believe this important devel-
opment should be delayed—for families
carrying mtDNA mutations, the clock is
ticking, and the desire to have children
free of mitochondrial DNA disease is
entirely justified. Ultimately, we believe
those that carry mitochondrial DNA
mutations must be fully informed of the
potential risks, and that they will decide
which option to take.
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